Positives

• Severe COVID-19 inpatients over 60 receiving Thymalin had hospital mortality cut roughly in half compared to standard care, with faster lymphocyte recovery and CRP normalization PMC.
  
  
• In vitro work showed Thymalin's KE and EW dipeptides reduced IL-1, IL-6, and TNF-alpha synthesis 1.4 to 6 fold, suggesting an anti-inflammatory profile a long COVID patient with persistent immune dysregulation may want MDPI.
  
  

Negatives

• A patient should note the strongest COVID outcome data are from acute hospitalized severe disease in older adults, not from outpatient long COVID, and applicability is unproven PMC.
  
  
• A patient reviewing safety data will find them limited to Russian studies, with no long-term Western pharmacovigilance on outpatient repeated dosing PMC.
  
  

Hurdles & Side Effects

• A US patient cannot obtain Thymalin through any FDA-approved channel and must rely on overseas pharmacies of variable regulation PMC.
  
  
• A patient using Thymalin must inject intramuscularly or subcutaneously rather than orally, requiring sterile technique and prescriber guidance many cannot access PMC.